Alnylam Pharmaceuticals (ALNY) Assets (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) reported Assets of $5.1 billion for Q1 2026, up 21.73% on a YoY basis from $4.2 billion in Q1 2025, and up 3.29% quarter-over-quarter from $5.0 billion in Q4 2025.
Alnylam Pharmaceuticals (ALNY) Assets (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals has reported Assets for 18 years, with the latest figure at $5.1 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets rose 21.73% year-over-year to $5.1 billion; the trailing twelve-month figure through Mar 2026 stood at $5.1 billion (up 21.73% YoY), and the FY2025 full-year result was $5.0 billion, up 17.13% from the prior year.
- Assets for Q1 2026 stood at $5.1 billion, up from $5.0 billion in the prior quarter.
- The five-year high for Assets was $5.1 billion in Q1 2026, with the low at $3.3 billion in Q2 2022.
- Historically, Assets has averaged $4.0 billion across 5 years, with a median of $3.8 billion in 2023.
- Annual changes were most pronounced in 2022 — Assets dropped 5.1% — and 2026, when it advanced 21.73%.
- Alnylam Pharmaceuticals' Assets stood at $3.5 billion in 2022, then climbed by 7.99% to $3.8 billion in 2023, then grew by 10.71% to $4.2 billion in 2024, then gained by 17.13% to $5.0 billion in 2025, then climbed by 3.29% to $5.1 billion in 2026.
- The last three Assets figures came in at $5.1 billion (Q1 2026), $5.0 billion (Q4 2025), and $4.9 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.13 Bn |
| Dec 31, 2025 | 4.97 Bn |
| Sep 30, 2025 | 4.85 Bn |
| Jun 30, 2025 | 4.57 Bn |
| Mar 31, 2025 | 4.21 Bn |
| Dec 31, 2024 | 4.24 Bn |
| Sep 30, 2024 | 4.21 Bn |
| Jun 30, 2024 | 4.01 Bn |
| Mar 31, 2024 | 3.82 Bn |
| Dec 31, 2023 | 3.83 Bn |
| Sep 30, 2023 | 3.84 Bn |
| Jun 30, 2023 | 3.40 Bn |
| Mar 31, 2023 | 3.39 Bn |
| Dec 31, 2022 | 3.55 Bn |
| Sep 30, 2022 | 3.54 Bn |
| Jun 30, 2022 | 3.33 Bn |
| Mar 31, 2022 | 3.43 Bn |
| Dec 31, 2021 | 3.64 Bn |
| Sep 30, 2021 | 3.47 Bn |
| Jun 30, 2021 | 3.51 Bn |